Your browser is no longer supported. Please, upgrade your browser.
Settings
BMY [NYSE]
Bristol-Myers Squibb Company
IndexS&P 500 P/E- EPS (ttm)-2.27 Insider Own0.10% Shs Outstand2.23B Perf Week-2.22%
Market Cap132.13B Forward P/E7.18 EPS next Y8.04 Insider Trans-15.90% Shs Float2.22B Perf Month-6.94%
Income-5079.00M PEG- EPS next Q1.93 Inst Own75.50% Short Float0.90% Perf Quarter-14.26%
Sales44.38B P/S2.98 EPS this Y-298.80% Inst Trans0.18% Short Ratio2.13 Perf Half Y-11.85%
Book/sh16.53 P/B3.49 EPS next Y7.48% ROA-4.30% Target Price80.24 Perf Year-5.41%
Cash/sh6.12 P/C9.43 EPS next 5Y6.72% ROE-12.50% 52W Range56.66 - 69.75 Perf YTD-6.98%
Dividend1.96 P/FCF17.75 EPS past 5Y-44.40% ROI-12.10% 52W High-16.33% Beta0.61
Dividend %3.40% Quick Ratio1.40 Sales past 5Y20.80% Gross Margin78.00% 52W Low3.00% ATR1.12
Employees30250 Current Ratio1.50 Sales Q/Q15.50% Oper. Margin-15.70% RSI (14)36.33 Volatility2.41% 1.86%
OptionableYes Debt/Eq1.23 EPS Q/Q- Profit Margin-11.40% Rel Volume1.01 Prev Close57.70
ShortableYes LT Debt/Eq1.15 EarningsOct 27 BMO Payout- Avg Volume9.35M Price58.36
Recom2.00 SMA20-1.50% SMA50-8.13% SMA200-8.99% Volume9,427,801 Change1.14%
Jul-27-21Resumed Truist Buy $74
Apr-30-21Downgrade Morgan Stanley Overweight → Equal-Weight $70 → $62
Apr-13-21Upgrade Truist Hold → Buy
Nov-16-20Upgrade Societe Generale Hold → Buy $76
Nov-10-20Resumed Bernstein Mkt Perform
Nov-06-20Downgrade Gabelli & Co Buy → Hold
Oct-19-20Upgrade Guggenheim Neutral → Buy $70
Sep-29-20Initiated Berenberg Buy $73
Jul-28-20Initiated Raymond James Outperform $75
Apr-02-20Upgrade Morgan Stanley Equal-Weight → Overweight $64
Mar-23-20Downgrade Societe Generale Buy → Hold $50
Feb-27-20Initiated Barclays Equal Weight $69
Jan-06-20Resumed Citigroup Buy $73
Dec-13-19Upgrade Argus Hold → Buy $80
Nov-22-19Resumed Morgan Stanley Equal-Weight $60
Oct-17-19Resumed BofA/Merrill Buy $60
Aug-14-19Upgrade Atlantic Equities Neutral → Overweight $63
May-28-19Initiated Goldman Buy
May-20-19Downgrade Argus Buy → Hold
May-03-19Upgrade Barclays Equal Weight → Overweight $53 → $55
Oct-15-21 10:00AM  
09:34AM  
09:29AM  
06:59AM  
Oct-14-21 10:30PM  
09:01AM  
Oct-13-21 10:36PM  
05:50PM  
06:59AM  
Oct-12-21 10:35PM  
04:30PM  
09:14AM  
08:06AM  
Oct-11-21 10:47PM  
03:51PM  
03:48PM  
03:15PM  
Oct-09-21 10:23AM  
Oct-08-21 10:50PM  
09:36AM  
09:04AM  
06:06AM  
06:05AM  
Oct-07-21 08:20PM  
05:45PM  
10:23AM  
06:59AM  
Oct-06-21 06:44PM  
08:28AM  
Oct-05-21 05:51AM  
Oct-04-21 05:50PM  
08:00AM  
Oct-02-21 11:30AM  
07:22AM  
Oct-01-21 08:25AM  
07:05AM  
07:00AM  
06:59AM  
05:55AM  
Sep-30-21 09:45AM  
Sep-29-21 06:25AM  
Sep-28-21 11:45AM  
10:17AM  
08:25AM  
06:04AM  
Sep-27-21 05:50PM  
11:55AM  
09:03AM  
08:34AM  
07:06AM  
05:56AM  
05:51AM  
Sep-26-21 09:31AM  
08:55AM  
Sep-25-21 12:48PM  
08:11AM  
Sep-23-21 09:01AM  
07:34AM  
05:51AM  
Sep-22-21 08:36AM  
Sep-21-21 10:59PM  
03:46PM  
09:39AM  
Sep-20-21 05:45PM  
10:57AM  
06:59AM  
Sep-18-21 09:13AM  
Sep-17-21 08:41AM  
06:59AM  
Sep-16-21 05:50PM  
02:01PM  
12:54PM  
07:49AM  
06:59AM  
Sep-15-21 10:00AM  
Sep-14-21 12:40PM  
Sep-13-21 11:02AM  
09:57AM  
07:05AM  
06:59AM  
Sep-10-21 08:15PM  
05:50PM  
06:30AM  
Sep-09-21 04:16PM  
Sep-08-21 01:48PM  
07:30AM  
07:10AM  
07:05AM  
06:59AM  
Sep-07-21 02:46PM  
06:59AM  
Sep-02-21 09:46AM  
Aug-31-21 01:25PM  
Aug-30-21 11:15AM  
08:27AM  
05:51AM  
Aug-27-21 01:10PM  
11:31AM  
Aug-26-21 11:47AM  
11:43AM  
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. The company also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; mpliciti for the treatment of multiple myeloma; and Reblozyl for the treatment of anemia in adult patients with beta thalassemia. In addition, it offers Onureg for the treatment of adult patients with AML; Zeposia to treat relapsing forms of multiple sclerosis; Vidaza for the treatment of myelodysplastic syndrome subtypes; Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B; and Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. The company sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. It has collaboration agreements with Pfizer, Inc.; Otsuka Pharmaceutical Co., Ltd.; Ono Pharmaceutical Co., Ltd.; Nektar Therapeutics; AVEO Pharmaceuticals, Inc.; Huyabio; DarwinHealth, Inc; and Bolt Biotherapeutics, Inc. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Caforio GiovanniBoard Chair and CEOSep 20Sale60.6425,0001,516,000483,980Sep 22 05:19 PM
Elkins David VEVP, Chief Financial OfficerAug 12Option Exercise48.4970,0003,394,300139,699Aug 16 05:51 PM
Elkins David VEVP, Chief Financial OfficerAug 12Sale66.9599,6916,674,49769,699Aug 16 05:51 PM
Powell AnnEVP, Chief Human ResourcesAug 03Sale68.5723,2801,596,31047,613Aug 04 04:46 PM
Caforio GiovanniChairman and CEOAug 02Sale68.5820,0001,371,600508,980Aug 04 04:47 PM
Elkins David VEVP, Chief Financial OfficerAug 01Option Exercise0.0046,4030133,435Aug 03 04:55 PM
VESSEY RUPERTEVP, Research & Early Dev.Jul 30Option Exercise58.49150,9678,830,108187,617Aug 03 04:50 PM
Dubow AdamSVP,ChiefCompliance&EthicsOff.Jul 30Sale67.902,466167,44113,777Aug 03 04:56 PM
LEUNG SANDRAEVP, General CounselJul 30Sale68.0429,3901,999,696339,967Aug 03 04:54 PM
VESSEY RUPERTEVP, Research & Early Dev.Jul 30Sale68.07158,39310,782,15436,650Aug 03 04:50 PM
von Autenried PaulEVP, Chief Information OfficerJul 30Sale68.0625,0001,701,375114,670Aug 03 04:49 PM
Santiago Karen MurphySVP & ControllerJul 01Option Exercise0.001,069015,045Jul 06 04:38 PM
Hirawat SamitEVP,Chief Med.Offr.,Drug Dev.Jul 01Option Exercise0.009,356016,538Jul 06 04:38 PM
Haller Julia ADirectorJun 13Option Exercise0.00902010,670Jun 14 06:56 PM
BONNEY MICHAEL WDirectorJun 13Option Exercise0.00902012,501Jun 14 06:56 PM
Eid JosephSVP,Head Glob. Medical AffairsJun 03Option Exercise0.002,154010,223Jun 04 04:36 PM
Haller Julia ADirectorJun 03Option Exercise0.002,94909,768Jun 04 04:35 PM
Schmukler Louis SEVP,Pres.,Glob.Prod. & SupplyMay 10Sale65.2515,000978,75031,956May 11 04:39 PM
Eid JosephSVP,Head Glob. Medical AffairsMay 10Sale65.001,11872,6708,069May 11 04:39 PM
VESSEY RUPERTEVP, Research & Early Dev.May 08Option Exercise0.0017,245062,384May 11 04:38 PM
VESSEY RUPERTEVP, Research & Early Dev.May 05Sale64.2930,5461,963,80245,139May 07 04:56 PM
Dubow AdamSVP,ChiefCompliance&EthicsOff.May 05Sale64.213,119200,27116,243May 07 04:57 PM
Mily ElizabethEVP, Strategy & BDApr 01Option Exercise0.006,34605,380Apr 02 01:14 PM
Caforio GiovanniChairman and CEOMar 22Sale62.2025,0001,555,000528,980Mar 24 04:41 PM
Dubow AdamSVP,ChiefCompliance&EthicsOff.Mar 10Option Exercise0.005,404019,811Mar 12 06:59 PM
BOERNER CHRISTOPHER S.EVP, Chief Commercial OfficerMar 10Option Exercise0.0025,215041,325Mar 12 06:59 PM
Caforio GiovanniChairman and CEOMar 10Option Exercise0.00200,7090603,187Mar 12 06:59 PM
Eid JosephSVP,Head Glob. Medical AffairsMar 10Option Exercise0.006,13409,862Mar 12 06:58 PM
Elkins David VEVP, Chief Financial OfficerMar 10Option Exercise0.008,025091,211Mar 12 06:57 PM
Hirawat SamitEVP,Chief Med.Offr.,Drug Dev.Mar 10Option Exercise0.004,18909,082Mar 12 06:56 PM
LEUNG SANDRAEVP, General CounselMar 10Option Exercise0.0050,3730383,564Mar 12 06:52 PM
Santiago Karen MurphySVP & ControllerMar 10Option Exercise0.007,483014,717Mar 12 06:50 PM
Powell AnnEVP, Chief Human ResourcesMar 10Option Exercise0.0029,835076,125Mar 12 06:51 PM
von Autenried PaulEVP, Chief Information OfficerMar 10Option Exercise0.0020,3020143,800Mar 12 06:50 PM
VESSEY RUPERTEVP, Research & Early Dev.Mar 10Option Exercise0.007,423079,051Mar 12 06:50 PM
Schmukler Louis SEVP,Pres.,Glob.Prod. & SupplyMar 10Option Exercise0.0031,575053,018Mar 12 06:50 PM
Elkins David VEVP, Chief Financial OfficerMar 01Option Exercise0.0024,579091,759Mar 03 05:27 PM
VESSEY RUPERTEVP, Research & Early Dev.Mar 01Option Exercise0.0023,349080,572Mar 03 05:26 PM
VESSEY RUPERTEVP, Research & Early Dev.Feb 04Option Exercise0.003,592058,409Feb 08 07:28 PM
Elkins David VEVP, Chief Financial OfficerDec 31Option Exercise0.0020,624079,111Jan 05 08:13 PM
VESSEY RUPERTEVP, Research & Early Dev.Dec 31Option Exercise0.0025,866068,074Jan 05 08:14 PM
AHMED NADIMEVP and President, HematologyDec 31Option Exercise0.0014,946046,549Jan 05 08:13 PM
Elkins David VEVP, Chief Financial OfficerDec 02Option Exercise0.008,792063,574Dec 03 08:24 PM
AHMED NADIMEVP and President, HematologyDec 02Option Exercise0.006,594034,983Dec 03 08:24 PM
VESSEY RUPERTEVP, Research & Early Dev.Dec 02Option Exercise0.008,792046,714Dec 03 08:24 PM
BOERNER CHRISTOPHER S.EVP, Chief Commercial OfficerDec 02Option Exercise0.002,637023,670Dec 03 08:23 PM
Eid JosephSVP,Head Glob. Medical AffairsDec 01Option Exercise0.002,82505,359Dec 03 05:15 PM
von Autenried PaulEVP, Chief Information OfficerNov 25Sale63.503190126,698Nov 30 05:52 PM
von Autenried PaulEVP, Chief Information OfficerNov 24Sale62.7520,0001,255,000126,701Nov 25 04:31 PM
Dubow AdamSVP,ChiefCompliance&EthicsOff.Nov 24Sale63.3990057,05115,186Nov 25 04:32 PM
VESSEY RUPERTEVP, Research & Early Dev.Nov 23Sale61.3413,421823,24437,922Nov 25 04:32 PM
VESSEY RUPERTEVP, Research & Early Dev.Nov 19Option Exercise49.2852,2132,572,88798,355Nov 23 05:40 PM
VESSEY RUPERTEVP, Research & Early Dev.Nov 19Sale61.3057,5913,530,26946,142Nov 23 05:40 PM
AHMED NADIMEVP and President, HematologyOct 30Option Exercise0.004,650030,680Nov 03 04:28 PM
VESSEY RUPERTEVP, Research & Early Dev.Oct 30Option Exercise0.005,804059,580Nov 03 04:27 PM